Werewolf Therapeutics Inc (HOWL)

$0.92 +0.07 (8.37%)
Market Cap 41.20M
Revenue (ttm) 1.89M
Net Income (ttm) -70.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,731.22%
Debt to Equity Ratio 0.29
Volume 163,300
Avg Vol 268,526
Day's Range N/A - N/A
Shares Out 44.83M
Stochastic %K 93%
Beta 0.48
Analysts Strong Sell
Price Target $10.17

Latest News on HOWL

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Apr 17, 2025, 8:00 AM EDT - 4 days ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 21 days ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 11, 2025, 7:00 AM EDT - 5 weeks ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Mar 4, 2025, 8:00 AM EST - 6 weeks ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Feb 24, 2025, 7:30 AM EST - 2 months ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Jan 13, 2025, 8:00 AM EST - 3 months ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 20, 2024, 8:00 AM EST - 5 months ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Nov 7, 2024, 9:02 AM EST - 5 months ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 7 months ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 7:05 AM EDT - 9 months ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jul 1, 2024, 10:04 AM EDT - 10 months ago

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 25, 2024, 7:00 AM EDT - 10 months ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Jun 1, 2024, 9:00 AM EDT - 11 months ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 11 months ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 11 months ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 3, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 4, 2024, 4:57 PM EDT - 1 year ago

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 6, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 8, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Jan 4, 2024, 4:05 PM EST - 1 year ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Dec 28, 2023, 7:09 PM EST - 1 year ago

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 22, 2023, 7:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 4:25 PM EST - 1 year ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Nov 6, 2023, 5:14 PM EST - 1 year ago

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 3, 2023, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Sep 11, 2023, 4:05 PM EDT - 1 year ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Aug 25, 2023, 4:48 PM EDT - 1 year ago

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:10 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics to Participate in May Investor Conferences

May 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Participate in May Investor Conferences

Werewolf Therapeutics: A Clinical Stage Biotech On The Hunt For Results In 2023

Apr 28, 2023, 3:30 PM EDT - 2 years ago

Werewolf Therapeutics: A Clinical Stage Biotech On The Hunt For Results In 2023

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

Apr 19, 2023, 10:00 AM EDT - 2 years ago

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

Mar 16, 2023, 7:30 AM EDT - 2 years ago

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

Mar 15, 2023, 7:30 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

Feb 24, 2023, 7:30 AM EST - 2 years ago

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

Feb 7, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2022, 9:00 AM EST - 2 years ago

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences

Nov 7, 2022, 4:05 PM EST - 2 years ago

Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences